Investigational Drug Information for PF-06826647
✉ Email this page to a colleague
What is the development status for investigational drug PF-06826647?
PF-06826647 is an investigational drug.
There have been 6 clinical trials for PF-06826647.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 27th 2019.
The most common disease conditions in clinical trials are Psoriasis, Colitis, and Hidradenitis Suppurativa. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are two US patents protecting this investigational drug and fifty-one international patents.
Summary for PF-06826647
| US Patents | 2 |
| International Patents | 51 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-06-27) |
| Vendors | 22 |
Recent Clinical Trials for PF-06826647
| Title | Sponsor | Phase |
|---|---|---|
| A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants | Pfizer | Phase 1 |
| A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis | Pfizer | Phase 2 |
| A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa | Pfizer | Phase 2 |
Clinical Trial Summary for PF-06826647
Top disease conditions for PF-06826647
Top clinical trial sponsors for PF-06826647
US Patents for PF-06826647
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-06826647 | ⤷ Sign Up | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| PF-06826647 | ⤷ Sign Up | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06826647
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-06826647 | Argentina | AR107714 | 2036-02-24 | ⤷ Sign Up |
| PF-06826647 | Australia | AU2017222417 | 2036-02-24 | ⤷ Sign Up |
| PF-06826647 | Brazil | BR112018015501 | 2036-02-24 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
